In 2018 about 70,000 people died from an unintentional drug overdose, 80,000 from alcohol, and approximately half a million from…
Daniel Schatz, MD
About Daniel Schatz, MD
Director of Program and Policy, Office of Behavioral Health, Health + Hospitals, NYU Langone
The New York State Department of Health, the New York State Office of Alcoholism and Substance Abuse (OASAS), and the New York State Buprenorphine Working Group wrote a Best Practice document focused on misconceptions related to the use of buprenorphine for the treatment of opioid use disorder (OUD). NYSAM Board Member, Dr. Dan Schatz, wrote a summary of the document reviewing five misconceptions of buprenorphine treatment.